Literature DB >> 19725053

Osteoblast differentiation is functionally associated with decreased AMP kinase activity.

Takayuki Kasai1, Kenjiro Bandow, Hiraku Suzuki, Norika Chiba, Kyoko Kakimoto, Tomokazu Ohnishi, Shin-ichiro Kawamoto, Eiichi Nagaoka, Tetsuya Matsuguchi.   

Abstract

Osteoblasts, originating from mesenchymal stem cells, play a pivotal role in bone formation and mineralization. Several transcription factors including runt-related transcription factor 2 (Runx2) have been reported to be essential for osteoblast differentiation, whereas the cytoplasmic signal transduction pathways controlling the differentiation process have not been fully elucidated. AMP-activated protein kinase (AMPK) is a serine-threonine kinase generally regarded as a key regulator of cellular energy homeostasis, polarity, and division. Recent lines of evidence have indicated that the activity of the catalytic alpha subunit of AMPK is regulated through its phosphorylation by upstream AMPK kinases (AMPKKs) including LKB1. Here, we explored the role of AMPK in osteoblast differentiation using in vitro culture models. Phosphorylation of AMPKalpha was significantly decreased during osteoblastic differentiation in both primary osteoblasts and MC3T3-E1, a mouse osteoblastic cell line. Conversely, the terminal differentiation of primary osteoblasts and MC3T3-E1 cells, represented by matrix mineralization, was significantly inhibited by glucose restriction and stimulation with metformin, both of which are known activators of AMPK. Matrix mineralization of MC3T3-E1 cells was also inhibited by the forced expression of a constitutively active form of AMPKalpha. Metformin significantly inhibited gene expression of Runx2 along with osteoblast differentiation markers including osteocalcin (Ocn), bone sialo protein (Bsp), and osteopontin (Opn). Thus, our present data indicate that differentiation of osteoblasts is functionally associated with decreased AMPK activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725053     DOI: 10.1002/jcp.21917

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  37 in total

1.  5-Aminoimidazole-4-carboxyamide ribonucleoside induces G(1)/S arrest and Nanog downregulation via p53 and enhances erythroid differentiation.

Authors:  Hee-Don Chae; Man-Ryul Lee; Hal E Broxmeyer
Journal:  Stem Cells       Date:  2012-02       Impact factor: 6.277

2.  Fibroblast growth factor-7 facilitates osteogenic differentiation of embryonic stem cells through the activation of ERK/Runx2 signaling.

Authors:  Young-Mi Jeon; Sung-Ho Kook; Sang-Jung Rho; Shin-Saeng Lim; Ki-Choon Choi; Hee-Soon Kim; Jong-Ghee Kim; Jeong-Chae Lee
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

Review 3.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

4.  Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.

Authors:  Sahar Kamal Hegazy
Journal:  J Bone Miner Metab       Date:  2014-03-15       Impact factor: 2.626

5.  AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.

Authors:  Hui Lin; Ying Ying; Yuan-Yuan Wang; Gang Wang; Shan-Shan Jiang; Deqinag Huang; Lingyu Luo; Ye-Guang Chen; Louis C Gerstenfeld; Zhijun Luo
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-08-25       Impact factor: 4.739

6.  AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass.

Authors:  M Shah; B Kola; A Bataveljic; T R Arnett; B Viollet; L Saxon; M Korbonits; C Chenu
Journal:  Bone       Date:  2010-04-24       Impact factor: 4.398

Review 7.  Diabetes medications and bone.

Authors:  Andrew Grey
Journal:  Curr Osteoporos Rep       Date:  2015-02       Impact factor: 5.096

8.  AMP-activated protein kinase regulates beta-catenin transcription via histone deacetylase 5.

Authors:  Jun-Xing Zhao; Wan-Fu Yue; Mei-Jun Zhu; Min Du
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

9.  Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice.

Authors:  Heeseog Kang; Benoit Viollet; Dianqing Wu
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

Review 10.  Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy.

Authors:  Antonio Desmond McCarthy; Ana María Cortizo; Claudia Sedlinsky
Journal:  World J Diabetes       Date:  2016-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.